We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
A total of 232 patients with inflammatory bowel disease (IBD; Crohn's disease, 101; ulcerative colitis, 93; indeterminate, 38) were diagnosed with COVID-19. After propensity score matching, the risk of severe COVID-19 was similar (RR, 0.93; P = .66). Patients taking biologics or immunomodulators were not at a higher risk of severe COVID-19 compared with IBD patients not on immune-mediated therapy (RR, 1.01; P = .97). The risk of severe COVID-19 was higher in the 71 IBD patients who received corticosteroids within the 3 months before the COVID-19 diagnosis (30.98%) compared with patients who did not (19.25%).
The composite outcome of hospitalization and mortality after COVID-19 in IBD patients is similar to that in patients without IBD. In addition, IBD patients with COVID-19 on long-term biologics or non-steroid immunomodulatory therapies did not have a higher risk of poor COVID-19 outcomes.
– Omar Khan, MD
This abstract is available on the publisher's site.
Patients with Inflammatory Bowel Disease (IBD), both Crohn's disease (CD) and Ulcerative Colitis (UC), may be at an increased risk for severe COVID-19 owing to their immunosuppressant medications or the chronic inflammatory disease state1. Recently, a worldwide registry (SECURE-IBD) consisting of physician-reported IBD patients with COVID-19 reported the clinical course of COVID-19 among IBD patients and the factors associated with severe COVID-192. However, there is limited data regarding the comparison of clinical characteristics and outcomes among IBD patients with COVID-19 and other patients. Moreover, the outcomes of IBD patients with COVID-19 predominantly in the United States, remain unexplored. Our study aimed to evaluate the characteristics and outcomes of IBD patients with COVID-19 in the United States and compare them to a large cohort of non-IBD patients with COVID-19.